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LETTER TO THE EDITOR
Rubella Virus-associated Anterior Uveitis in a
Vaccinated Patient: A Case Report
Josianne C. E. M. ten Berge, MD, MSc1, Paul L. A. van Daele, MD, PhD2, and
Aniki Rothova, MD, PhD1
1Department of Ophthalmology, Erasmus MC, University Medical Center Rotterdam,
Rotterdam, The Netherlands, and 2Department of Immunology, Erasmus MC, University Medical Center
Rotterdam, Rotterdam, The Netherlands
ABSTRACT
Rubella virus is involved in the pathogenesis of Fuchs heterochromic uveitis and almost all cases in
Europe show an active antibody production in the aqueous humor against rubella virus. Herein we report a
case of a fully vaccinated patient with common variable immunodeficiency who developed unilateral Fuchs
heterochromic uveitis secondary to rubella virus which was proven by intraocular fluid examination.
Awareness of rubella associated anterior uveitis should remain also in vaccinated patients, especially those
without a fully competent immune system.
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Rubella virus (RV) is involved in the pathogenesis of
Fuchs heterochromic uveitis (FHU) and almost all
cases of FHU in Europe show an active antibody
production in the aqueous humor against RV.1
Positive polymerase chain reaction (PCR) for RV is,
however, scarcely detected, probably due to chronic
stage of the infection at the time of intraocular sample
collection. The incidence rate of FHU cases has
significantly decreased since the introduction of the
rubella vaccination schedule.2 Herein we report a case
of a fully vaccinated patient who developed unilateral
FHU secondary to RV.
A 28-year-old man was referred with unilateral
uveitis, not responding to anti-inflammatory treat-
ment. His complaints included gradual vision loss in
primarily the right eye since 1 year. Medical history of
the patient includes a parotic extranodular marginal
zone non-Hodgkin B-cell lymphoma at the age of 21,
for which he was treated with local radiotherapy.
Additionally, he was diagnosed with a common
variable immune deficiency (CVID). CVID is a form
of immune deficiency that is characterized by a
decreased but not absent antibody production. Since
childhood he has suffered from recurrent upper
respiratory tract infections. Currently he receives
regular immunoglobulin supplementation.
Ophthalmic examination revealed a corrected visual
acuity of 0.8++ of the right eye and 1.5- of the left eye.
Intraocular pressure was 9 mmHg. There was no
conjunctival injection and slit-lamp examination of
the right eye disclosed fine keratic precipitates
diffusely scattered across the corneal endothelium,
anterior chamber cells and a slight opalescence,
diffuse iris atrophy with transillumination, and fine
nodules at the pupillary border. No synechiae were
found. Fundus investigation and the optic disc
showed no abnormalities. The left eye exhibited no
anomalous findings. Aqueous examination showed
anti-rubella IgG in a titer of 2560 UI/mL (which was
higher than his serum titer of 1280 UI/mL), and
resulted in a Goldmann-Witmer coefficient (GWC) of
182. The PCR and GWC for herpes simplex virus 1
and 2, cytomegalovirus, varicella zoster virus, and
Epstein Barr virus were negative as well as the PCR
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for RV. All additional screening results for uveitis
(including a chest x-ray, a Mantoux test, serum
angiotensine-converting-enzyme levels, and serology
for Borrelia burgdorferi, Toxoplasma gondii, and
Treponema pallidum) remained within the normal
limits. The diagnosis of RV-associated uveitis was
made and it became apparent that his uveitis has no
relation to previous lymphoma, but that regular
ocular controls were required. Minimal use of topical
corticosteroid medication was prescribed since it is
known that corticosteroids have less beneficial effects
in RV-associated uveitis and might contribute to
cataract and glaucoma development.
Systemic RV infections occurring in fully
RV-vaccinated patients have already been reported.3
The duration of rubella immunity induced by 2-dose
RV vaccination has resulted in a low level of
antibodies against RV 15 years after vaccination in
up to 31%.4 The patient received rubella vaccination at
the ages of 4 and 9. The vaccination status was
confirmed by the National Institute for Public Health
and the Environment.
The titers of antibodies against rubella determined
at the age of 24 and 28 were high and protective in
contrast to his marginal titer of antibodies against
mumps and measles, which suggests a real previous
infection with rubella virus. So far, the efficacy data of
RV vaccination in immunocompromised patients are
lacking. We hypothesize that the RV-associated uveitis
in this fully vaccinated but immunocompromised
patient might have developed due to an insufficient
reaction to vaccine or to a premature loss of immunity
against RV despite the vaccination, probably also
caused by the immunodeficiency. Influence of the
treatment of the non-Hodgkin B-cell lymphoma on
the development of rubella-associated uveitis is not
likely, since he was treated with local radiotherapy.
To our knowledge this is the first report showing
RV-associated FHU in a fully vaccinated patient.
Rubella vaccination does not provide protection for
everyone and reinfections with RV are possible. Our
case indicates that awareness of rubella-associated
anterior uveitis should also remain in vaccinated
patients, especially those without a fully competent
immune system.
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